Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8886794 | 0.98 | MEN1 (0.47) | MEN1KMT2APOLBL3MBTL1PKM | |
| SCHEMBL14747833 | 0.96 | L3MBTL1 (0.53) | MEN1KMT2APOLBL3MBTL1PKM | |
| SCHEMBL2001036 | 0.89 | L3MBTL1 (0.43) | MEN1KMT2APOLBL3MBTL1PKM | |
| SCHEMBL6376058 | 0.83 | P2RY14 (0.50) | GAA | |
| SCHEMBL1185244 | 0.81 | KMT2A (0.58) | MEN1KMT2AL3MBTL1PKM | |
| SCHEMBL2348474 | 0.81 | KMT2A (0.44) | MEN1KMT2APOLBL3MBTL1PKM | |
| Hydrochloric Acid SCHEMBL29568124 | 0.80 | KMT2A (0.57) | MEN1KMT2AL3MBTL1PKM | |
| Hydrochloric Acid SCHEMBL3839558 | 0.80 | KMT2A (0.57) | MEN1KMT2AL3MBTL1PKM | |
| SCHEMBL15456304 | 0.80 | ALDH1A1 (0.59) | MEN1KMT2APOLBKDM4EGAA | |
| Water SCHEMBL8887942 | 0.79 | KMT2A (0.42) | MEN1KMT2APOLBL3MBTL1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5602277-A | Substituted benzene derivatives useful as neuraminidase inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-02-11 | — | — | US | claimed |
| WO-1996030329-A1 | SUBSTITUTED BENZENE DERIVATIVES USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INCORPORATED (US) | 1996-10-03 | — | — | WO | claimed |
| EP-3320921-B1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA INC (US) | 2022-01-05 | — | — | EP | disclosed |
| US-20180153817-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| EP-3320921-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | Ala Wai Pharma, Inc. (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-2217216-B1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA INC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20170157059-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9579383-B2 | Formulations for enhanced bioavailability of orally administered polar agents | ALA WAI PHARMA, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20140072627-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | ALA WAI PHARMA, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8609139-B2 | Formulations for enhanced bioavailability of orally administered polar agents | ALA WAI PHARMA, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20110206764-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | UNIVERSITY OF HAWAII | 2011-08-25 | — | — | US | disclosed |
| US-7960459-B2 | Curable composition | KANEKA CORPORATION (JP) | 2011-06-14 | — | — | US | disclosed |
| EP-1990371-B1 | CURABLE COMPOSITION | KANEKA CORP (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20090186993-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-1990371-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2008-11-12 | — | — | EP | disclosed |
| US-5602277-A | Substituted benzene derivatives useful as neuraminidase inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157059-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SLC35A1, SLC29A2, NEU2 | MEN1 2103/4885KMT2A 4278/4885POLB 1531/4885 |
| US-20110206764-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SLC35A1, SLC29A2, NEU2 | MEN1 2103/4885KMT2A 4278/4885POLB 1531/4885 |
| US-20180153817-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SLC35A1, SLC29A2, NEU2 | MEN1 2103/4885KMT2A 4278/4885POLB 1531/4885 |
| US-20140072627-A1 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS | SLC35A1, SLC29A2, NEU2 | MEN1 2103/4885KMT2A 4278/4885POLB 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.